Advanced search
Publication Cover
Acta Cardiologica Volume 59, 2004 - Issue 2
Submit an article Journal homepage
11
Views
4
CrossRef citations to date
0
Altmetric
Original Articles

Obstacles to cardiovascular prevention in general practice

Régis De MuylderSchool of Public Health, Units of Epidemiology Brussels, Belgium.
,
Vincent LorantUnits of Social Economy Brussels, Belgium.
,
Dominique PaulusUnits of University Centre of General Practice Brussels, Belgium.
,
Fabienne NackersSchool of Public Health, Units of Epidemiology Brussels, Belgium.
,
Michel JeanjeanSchool of Public Health, Units of Epidemiology Brussels, Belgium.
&
Benoit BolandSchool of Public Health, Units of Epidemiology Brussels, Belgium.;Department of Internal Medicine, Université catholique de Louvain, Brussels, Belgium.Correspondence[email protected]
Pages 119-125 | Received 06 Mar 2003, Accepted 17 Jun 2003, Published online: 23 May 2017

References

  • Komitzer M, De Bacquer D, De Backer G. Hyperc-holestérolémie en Belgique, Année 1996: le point de vue de l’épidémiologiste (Hypercholestemlemia in Belgium anno 1996: view of the epidemiologist). Rev Med Brux 1997; 18: 16–25.
  • Wood D, De Backer G, Faergeman 0, Graham I, Mancia G, Pyorala K. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention. Eur Heart J 1998; 19:1434–1503.
  • Risk in cardiovascular disease [theme issue] BMJ 2000; 320: 659–724.
  • Tunstall-Pedoe H, Kuulasmaa K, Mähönen M, Tolonen H, Ruokokski E, Amouyel Ph, for the WHO MONICA Project. Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA Project populations. Lancet 1999; 353: 1547–57.
  • De Henauw S, De Bacquer D, de Smet P, Komitzer M, De Backer G. Trends in coronary heart disease in two Belgian areas: results from the MONICA Ghent-Charleroi study. J Epidemiol Community Health 1999; 53: 89–98.
  • EUROASPIRE Study group. A European Society of cardi-ology survey of secondary prevention of coronary heart disease: principal results. Eur Heart J 1997; 18: 1569–82.
  • EUROASPIRE II group. Lifestyle and risk factor manage-ment and use of drug therapies in coronary patients from 15 countries: principal results from Euroaspire II. Eur Heart J 2001; 22: 554–72.
  • EUROASPIRE I and II group. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. Lancet 2001; 357: 995–1001.
  • Rosamond WD, Chambless LE, Folsom AR, Cooper LS, Conwill DE, Clegg L, Wang CH, Heiss G. Trends in the incidence of myocardial infarction and in mortality due to coronary heart disease, 1987 to 1994. N Engl J Med 1998; 339: 861–7.
  • Grover SA, Lowensteyn I, Esrey K, Steinert Y, Joseph L, Abrahamowicz M. Do doctors accurately assess coronary risk in their patients? Preliminary results of the coronary health assessment study. BMJ 1995; 310: 975–8.
  • Barclay S, Todd C, Finlay I, Grande G, Wyatt P. Not another questionnairel Maximizing the response rate, predicting non-response and assessing non-response bias in postal ques-tionnaire studies of GPs. Fam Pract 2002; 19: 105–11.
  • Felder G, Eccles M, Gral R, Griffiths C, Grimthaw J. Using clinical guidelines. BMJ 1999; 318: 728–30.
  • Neaton JM, Blackburn H, Jacobs D, Kuller L, Lee DJ, Sherwin R, Shih J, Stamler J, Wentworth D. Serum choles-terol level and mortality findings for men screened in the Multiple Risk Factor Intervention Trial. Arch Int Med 1992; 152: 1490–500.
  • Assmann G, Cullen P, Schulte H. The Munster Heart Study (PROCAM). Results of follow-up at 8 years. Eur Heart J 1998; 19 Suppl A:A2–11.
  • Enbergs A, Burger R, Reinecke H, Borggrefe M, Breithardt G, Kerber S. Prevalence of coronary artery disease in a general population without suspicion of coronary artery disease: angiographic analysis of subjects aged 40 to 70 years referred for catheter ablation therapy. Eur Heart J2000; 21: 45–52.
  • van der Weijden T, Grol R, Schouten BJ, Knottnerus A. Barriers to working according to cholesterol guidelines: a randomized controlled trial on implementation of national guidelines in 20 general practices. Eur J Public Health 1998; 8: 113–18.
  • Muls E, De Backer G, De Bacquer D, Brohet C, Heller F. Lipi-Watch, a Belgian/Luxembourg survey on achievement of European Atherosclerosis Society Lipid Goals. Clin Drug Invest 2000; 19: 219–29.
  • West of Scotland Coronary Prevention Group. West of Scot-land Coronary Prevention study: identification of high-risk groups and comparison with other cardiovascular interven-tion trials. Lancet 1996; 348: 1339–42.
  • Maher V, Sinfuego J, Pao P, Parekh J. Primary prevention of coronary heart disease. What has WOSCOPS told us and what questions remain? Drugs 1997; 54: 1–8.
  • Sherpherd J. Economics of lipid lowering in primary pre-vention: lessons from the West of Scotland Coronary Pre-vention Study. Am J Cardiol 2001; 87: S19–22.
  • Rosenberg W, Donald A. Evidence-based medicine: an approach to clinical problem solving. BMJ 1995; 310: 1122–6.
  • McAlister FA, Graham I, Karr GW, Laupacis A. Evidence-based medicine and the practicing clinician. J Gen Intern Med 1999; 14: 236–42.
  • van der Weijden T, Dansen A, Schouten BJ, Knottnerus JA, Grol RP. Comparison of appropriateness of cholesterol test-ing in general practice with the recommendations of national guidelines: an audit of patient records in 20 general practices. Qual Health Care 1996; 5: 218–22.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

A worldwide pioneer in biotechnology.
Novartis. Your partner in Heart Failure & Atherosclerosis >>

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.